Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK598809, using-PHNO · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GSK598809, using [11C]-(+)-PHNO | DRUG | - |
Inclusion Criteria: Healthy male subjects, defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests. * Aged 25-55 years inclusive, at screening visit. * Bo...
GSK598809 is an investigational small molecule being studied for substance dependence, including nicotine reward and food reward, in healthy subjects. It is in Phase 1 clinical development and has not been approved by the FDA.
GSK598809 is a D3 antagonist, meaning it blocks the dopamine D3 receptor. This mechanism is being studied for its effects on reward and reinforcement related to substance dependence.
GSK598809 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK.
GSK598809 is in Phase 1 clinical development. All seven clinical trials listed for the drug are completed, with no active trials currently ongoing.
GSK598809 has completed Phase 1 trials including NCT00605241, NCT00728052, NCT00728897, and NCT01039454. These studies investigated its effects on nicotine reward, food reward, and bioavailability in healthy volunteers.
Yes, GSK598809 is a D3 antagonist. It works by blocking the dopamine D3 receptor, which is being studied for its potential role in modulating reward pathways associated with substance dependence.